- Home
- AVD vs PLX Comparison
AVD vs PLX Comparison
Compare AVD & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVD
- PLX
- Stock Information
- Founded
- AVD 1969
- PLX 1993
- Country
- AVD United States
- PLX Israel
- Employees
- AVD N/A
- PLX N/A
- Industry
- AVD Agricultural Chemicals
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AVD Industrials
- PLX Health Care
- Exchange
- AVD Nasdaq
- PLX Nasdaq
- Market Cap
- AVD 165.8M
- PLX 160.2M
- IPO Year
- AVD N/A
- PLX 1998
- Fundamental
- Price
- AVD $5.21
- PLX $2.33
- Analyst Decision
- AVD Strong Buy
- PLX
- Analyst Count
- AVD 3
- PLX 0
- Target Price
- AVD $16.67
- PLX N/A
- AVG Volume (30 Days)
- AVD 357.2K
- PLX 553.9K
- Earning Date
- AVD 03-13-2025
- PLX 03-13-2025
- Dividend Yield
- AVD 1.16%
- PLX N/A
- EPS Growth
- AVD N/A
- PLX N/A
- EPS
- AVD N/A
- PLX N/A
- Revenue
- AVD $553,839,000.00
- PLX $45,667,000.00
- Revenue This Year
- AVD N/A
- PLX N/A
- Revenue Next Year
- AVD $5.98
- PLX $90.00
- P/E Ratio
- AVD N/A
- PLX N/A
- Revenue Growth
- AVD N/A
- PLX N/A
- 52 Week Low
- AVD $4.26
- PLX $0.82
- 52 Week High
- AVD $14.28
- PLX $2.36
- Technical
- Relative Strength Index (RSI)
- AVD 58.04
- PLX 78.72
- Support Level
- AVD $4.46
- PLX $2.11
- Resistance Level
- AVD $5.01
- PLX $2.36
- Average True Range (ATR)
- AVD 0.24
- PLX 0.12
- MACD
- AVD 0.10
- PLX 0.00
- Stochastic Oscillator
- AVD 93.97
- PLX 94.23
About AVD American Vanguard Corporation ($0.10 Par Value)
American Vanguard Corp is a United States-based diversified specialty and agricultural products company. It manufactures and formulates chemicals for crops, turf and ornamental plants, and human and animal health protection. These chemicals include insecticides, fungicides, herbicides, molluscicides, growth regulators, and soil fumigants, which are marketed in liquid, powder, and granular forms.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.